Thermo Fisher Q1 2026 Earnings Beat Expectations, Shares Drop Ahead of Full-Year Outlook

Thermo Fisher Scientific beat Wall Street expectations in its Q1 2026 earnings report, yet the stock price declined in response to its forward-looking guidance. Although the company delivered solid first-quarter results, investors remain uncertain about its future growth prospects due to factors like soft organic growth and weakening trends in diagnostics and instruments.

In a positive development, the company reiterated a buy rating due to core growth, AI, and reshoring catalysts. However, the full-year outlook remains a key concern for investors. With growth and revenue growth metrics topping estimates, the market's mixed reaction suggests that more information about the company's future plans and prospects is needed.

Looking ahead, TMO reiterated full-year guidance of $47.3-48.1 billion in revenue with 3-4% organic growth and adjusted EPS of $24.64-$25.12. Achieving that target requires meaningful organic growth acceleration through Q2-Q4, as Q1 came in at just 1% organic. Tariffs weighed approximately 80 basis points on Q1 adjusted operating margins, and management has embedded its PPI (Productivity, Process, Innovation) business system as the primary offset — though guidance explicitly assumes no worsening from current tariff levels. Investors will treat Q2 as the critical test of whether the ramp materializes, with China and U.S. academic/government end markets needing to stabilize for the thesis to hold.